{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:34:58Z","timestamp":1789788898132,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF 23-138"],"award-info":[{"award-number":["BCRF 23-138"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10549-025-07781-9","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T04:00:20Z","timestamp":1752811220000},"page":"273-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS"],"prefix":"10.1007","volume":"213","author":[{"given":"Haiying","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nay Nwe Nyein","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revekka","family":"Khaimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thazin N.","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gaule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"7781_CR1","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1038\/s41598-019-46309-2","volume":"9","author":"AJ Kole","year":"2019","unstructured":"Kole AJ et al (2019) Overall survival is improved when DCIS accompanies invasive breast cancer. Sci Rep 9:9934","journal-title":"Sci Rep"},{"key":"7781_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41416-020-01212-w","volume":"124","author":"Y Zeng","year":"2021","unstructured":"Zeng Y, Gao W, Chen X, Shen K (2021) Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component. Br J Cancer 124:975\u2013981","journal-title":"Br J Cancer"},{"key":"7781_CR3","doi-asserted-by":"publisher","first-page":"103777","DOI":"10.1016\/j.breast.2024.103777","volume":"77","author":"Y Bar","year":"2024","unstructured":"Bar Y et al (2024) The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer. Breast 77:103777","journal-title":"Breast"},{"key":"7781_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molonc.2009.03.001","volume":"3","author":"W Zhou","year":"2009","unstructured":"Zhou W et al (2009) Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution. Mol Oncol 3:214\u2013219","journal-title":"Mol Oncol"},{"key":"7781_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.molonc.2010.06.007","volume":"4","author":"AA Muggerud","year":"2010","unstructured":"Muggerud AA et al (2010) Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol 4:357\u2013368","journal-title":"Mol Oncol"},{"key":"7781_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s10549-011-1894-3","volume":"133","author":"ES Knudsen","year":"2012","unstructured":"Knudsen ES et al (2012) Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat 133:1009\u20131024","journal-title":"Breast Cancer Res Treat"},{"key":"7781_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/path.3990","volume":"227","author":"L Hernandez","year":"2012","unstructured":"Hernandez L et al (2012) Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol 227:42\u201352","journal-title":"J Pathol"},{"key":"7781_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-012-2123-4","volume":"135","author":"AC Vargas","year":"2012","unstructured":"Vargas AC et al (2012) Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. Breast Cancer Res Treat 135:153\u2013165","journal-title":"Breast Cancer Res Treat"},{"key":"7781_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.breast.2014.01.015","volume":"23","author":"M Dieterich","year":"2014","unstructured":"Dieterich M et al (2014) Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. Breast 23:346\u2013351","journal-title":"Breast"},{"key":"7781_CR10","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1158\/0008-5472.CAN-22-0090","volume":"82","author":"M Tokura","year":"2022","unstructured":"Tokura M et al (2022) Single-cell transcriptome profiling reveals intratumoral heterogeneity and molecular features of ductal carcinoma in situ. Cancer Res 82:3236\u20133248","journal-title":"Cancer Res"},{"key":"7781_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13058-024-01875-w","volume":"26","author":"MR Van Bockstal","year":"2024","unstructured":"Van Bockstal MR et al (2024) Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance. Breast Cancer Res 26:125","journal-title":"Breast Cancer Res"},{"key":"7781_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/tbj.12735","volume":"23","author":"P Di Cesare","year":"2017","unstructured":"Di Cesare P et al (2017) The relationships between HER2 Overexpression and DCIS characteristics. Breast J 23:307\u2013314","journal-title":"Breast J"},{"key":"7781_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-019-0436-3","volume":"120","author":"IM Miligy","year":"2019","unstructured":"Miligy IM et al (2019) The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. Br J Cancer 120:1075\u20131082","journal-title":"Br J Cancer"},{"key":"7781_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/annonc\/mdw623","volume":"28","author":"G Pruneri","year":"2017","unstructured":"Pruneri G et al (2017) The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol 28:321\u2013328","journal-title":"Ann Oncol"},{"key":"7781_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/annonc\/mdv013","volume":"26","author":"G Curigliano","year":"2015","unstructured":"Curigliano G et al (2015) Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann Oncol 26:682\u2013687","journal-title":"Ann Oncol"},{"key":"7781_CR16","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-21-1239","volume":"27","author":"MA Thorat","year":"2021","unstructured":"Thorat MA et al (2021) Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: results from the UK\/ANZ DCIS randomized trial. Clin Cancer Res 27:5317\u20135324","journal-title":"Clin Cancer Res"},{"key":"7781_CR17","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1200\/JCO.20.02824","volume":"39","author":"MA Cobleigh","year":"2021","unstructured":"Cobleigh MA et al (2021) Comparison of radiation with or without concurrent trastuzumab for HER2-positive ductal carcinoma in situ resected by lumpectomy: a phase III clinical trial. J Clin Oncol 39:2367\u20132374","journal-title":"J Clin Oncol"},{"key":"7781_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes J et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386:1143\u20131154","journal-title":"N Engl J Med"},{"key":"7781_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S et al (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 387:9\u201320","journal-title":"N Engl J Med"},{"key":"7781_CR20","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A et al (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391:2110\u20132122","journal-title":"N Engl J Med"},{"key":"7781_CR21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1056\/NEJM198811103191902","volume":"319","author":"MJ van de Vijver","year":"1988","unstructured":"van de Vijver MJ et al (1988) Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239\u20131245","journal-title":"N Engl J Med"},{"key":"7781_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/jcp.44.3.211","volume":"44","author":"S Soomro","year":"1991","unstructured":"Soomro S, Shousha S, Taylor P, Shepard HM, Feldmann M (1991) c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol 44:211\u2013214","journal-title":"J Clin Pathol"},{"key":"7781_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/jcp.45.1.16","volume":"45","author":"JE Somerville","year":"1992","unstructured":"Somerville JE, Clarke LA, Biggart JD (1992) c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol 45:16\u201320","journal-title":"J Clin Pathol"},{"key":"7781_CR24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/0046-8177(92)90257-4","volume":"23","author":"DC Allred","year":"1992","unstructured":"Allred DC et al (1992) Overexpression of HER-2\/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974\u2013979","journal-title":"Hum Pathol"},{"key":"7781_CR25","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1093\/annonc\/mdx253","volume":"28","author":"M Van Bockstal","year":"2017","unstructured":"Van Bockstal M, Libbrecht L, Floris G, Lambein K, Pinder S (2017) Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma? Ann Oncol 28:2317","journal-title":"Ann Oncol"},{"key":"7781_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF00689717","volume":"34","author":"JD Iglehart","year":"1995","unstructured":"Iglehart JD, Kerns BJ, Huper G, Marks JR (1995) Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 34:253\u2013263","journal-title":"Breast Cancer Res Treat"},{"key":"7781_CR27","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/01.MP.0000038462.62634.B1","volume":"15","author":"EK Latta","year":"2002","unstructured":"Latta EK, Tjan S, Parkes RK, O\u2019Malley FP (2002) The role of HER2\/neu overexpression\/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 15:1318\u20131325","journal-title":"Mod Pathol"},{"key":"7781_CR28","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1365-2559.2006.02403.x","volume":"48","author":"K Park","year":"2006","unstructured":"Park K, Han S, Kim HJ, Kim J, Shin E (2006) HER2 status in pure ductal carcinoma and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence hybridization and immunohistochemistry. Histopathology 48:702\u2013707","journal-title":"Histopathology"},{"key":"7781_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/s41374-022-00804-9","volume":"102","author":"M Moutafi","year":"2022","unstructured":"Moutafi M et al (2022) Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Lab Invest 102:1101\u20131108","journal-title":"Lab Invest"},{"key":"7781_CR30","doi-asserted-by":"crossref","unstructured":"Trontzas IP et al (2025) Quantitative protein expression of antibody-drug conjugate targets in EGFR mutated and wild-type non-small cell lung cancer. Clin Cancer Res","DOI":"10.1158\/1078-0432.c.7903399"},{"key":"7781_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12032-022-01876-9","volume":"40","author":"I Akrida","year":"2022","unstructured":"Akrida I, Mulita F (2022) The clinical significance of HER2 expression in DCIS. Med Oncol 40:16","journal-title":"Med Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07781-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07781-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07781-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:41:00Z","timestamp":1757252460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07781-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7781"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07781-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Rimm has served as a Consultant\/Advisor to Astra Zeneca, Cell Signaling Technology, Cepheid, Danaher, Halda Therapeutics, Incendia, NextCure, Nucleai, PAIGE.AI, Regeneron, and Sanofi.  Astra Zeneca, Cepheid, NavigateBP, NextCure, Danaher\/Leica, Regeneron and Konica\/Minolta currently fund, or have previously funded, research in his lab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the IRB at Yale University. This study was retrospective in nature and all information was properly de-identified; therefore, ethics approval and consent were waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}